Skip to main content
Premium Trial:

Request an Annual Quote

ACD Announces Preferred Partnership with MicroMatrices

NEW YORK (GenomeWeb) – Advanced Cell Diagnostics announced today a preferred partnership agreement with Dundee, UK-based MicroMatrices to develop applications of its RNAscope technology.

ACD's RNAscope assays allow for single RNA molecule detection of formalin-fixed, paraffin-embedded tissue samples, offering quantitative molecular detection with morphological context in a single assay. MicroMatrices has expertise in using RNAscope to detect RNA-based biomarkers in situ, the companies said in a statement, and will now aim to develop preclinical applications of the technology.

"The power and versatility of RNAscope has been an invaluable tool to enable us to solve mode of action/efficacy/toxicity challenges for our clients in the pharmaceutical, agrochemical, and chemical industries," Simon Plummer, managing director of MicroMatrices, said.

Financial and other terms of the deal were not provided.

MicroMatrices is a service provider specializing in high resolution cell type-specific analysis to characterize toxicological responses in different cell types and tissues.

Hayward, Calif.-based ACD develops cell and tissue-based diagnostic tests for personalized medicine.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.